The efficacy of a human interleukin 12/23 monoclonal antibody and investigation of expression of IL12/23p40 in Crohn disease anorectal lesion.

Not Applicable

• Conditions: Crohn' s disease

• Registration Number: JPRN-UMIN000028761
• Lead Sponsor: Hyogo College of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-08-21
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

Age under 10 yrs. Patients without consent.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the efficacy of a human interleukin 12/23 monoclonal antibody in Crohn's disease anorectal lesion

Secondary Outcome Measures

Name	Time	Method
A Blood cytokine expression status before and after administration of a human interleukin 12/23 monoclonal antibody